T2	Participants 204 244	percutaneous coronary intervention (PCI)
T1	Participants 52 55	PCI
T3	Participants 323 472	5362 patients who had not been treated with clopidogrel to receive either cangrelor or placebo at the time of PCI, followed by 600 mg of clopidogrel.
T4	Participants 474 592	he primary end point was a composite of death, myocardial infarction, or ischemia-driven revascularization at 48 hours
T5	Participants 744 821	primary end point occurred in 185 of 2654 patients receiving cangrelor (7.0%)
T6	Participants 1707 1710	PCI
T7	Participants 1755 1772	primary end point
